Objectives: Clinical and experimental observations reveal the exact role of vitamin D in prostate cancer. Yet, a complete understanding of the issue necessitates the evaluation of the exquisite mechanisms that involve full actors of the calcium homeostasis in relation. Background: Besides the role of vitamin D, parathyroid hormone (PTH) is now understood to be a mitogen for prostate cancer cells, and calcium has already been known for such role. The interplay between renin-angiotensin-aldosterone system effector hormones and calcium homeostasis attracts attention in recent studies. Methods: Twenty fi ve patients with prostate cancer (median age 66 (62-67) years) who had presented at the Urology Outpatient Clinic were prospectively included in the study. Also, 30 volunteer controls (median age 63 (60-70) years) were enrolled for comparison. Serum total PSA, intact PTH, calcium, aldosterone and 25-hydroxy vitamin D levels were detected in a selected group of patients with prostate cancer.
The major features of the descriptive epidemiology of prostate cancer (PCA), i.e. increasing incidence with age, black race and residence at northern latitudes, resembled the descriptive epidemiology of vitamin D defi ciency (1) . Several ecological studies have shown a relationship between lower sunshine exposure and higher prostate cancer prevalence or mortality. Subsequent clinical observations support the hypothesis that vitamin D may become an agent to prevent the development of prostate cancer (2, 3) .
Human prostate cells express the receptor for vitamin D (4) . It is shown that many genes in prostate cancer cells are positively or negatively regulated through the vitamin D receptor (5) . In general 1,25-dihydroxyvitamin D, (1,25(OH)2D) suppresses proliferation and stimulates differentiation of cancer cells.
The circulating 1,25(OH)2D is formed in the kidney under stimulation of PTH and negative feedback by serum calcium and itself.
Conversely, increased exposure to UV light, increased dietary intakes of calcium and of vitamin D down-regulate production of PTH.
Concerning the close relationship with vitamin D, PTH is a suspicious cancer promoter. PTH promotes the proliferation and migration of prostate cancer cells and negatively predicts survival. Also, high intake of dietary calcium has already been reported to be an increased risk of prostate cancer (6) .
In extrarenal cells and tissues 25-hydroxyvitamin D (25(OH)D) can be hydroxylated to 1,25(OH)2D under the infl uence of cytokines. This extrarenal 1,25(OH)2D stimulates cell differentiation in a paracrine way and might play a role in cancer prevention (7) .
In addition to its role in calcium and phosphate homeostasis, 1,25(OH)2D infl uences a wide variety of other biological processes, including the immune response, insulin secretion, cardiovascular function, and blood pressure.
1,25(OH)2D has been identifi ed recently as a regulator of the renin-angiotensin-aldosterone system. Aldosterone and 1,25(OH)2D co-operates in the regulation of cell function and this interaction seems to be the result of cross talk between nongenomic and genomic steroid hormone signaling pathways (8) .
Thus, it is critical to understand what factors may regulate the conversion of 25(OH)D to 1,25(OH)2D within prostate cells. In this report we examined major actors that are likely to take part as regulators of vitamin D, in very delicately selected groups of patients and controls.
Material and methods

Study population and clinical examinations
Twenty fi ve patients with prostate cancer (median age 66 (62-71) years) who had presented at the Urology Outpatient Clinic were prospectively included in the study. Also, 30 volunteer controls (median age 63 (60-70)years) were enrolled for comparison.
The patients were evaluated by the same urologist. All subjects had full physical examination and were asked to complete a general questionnaire and gave informed consent before the onset of study. The questions included: the age, social-economic status, origin of ancestors, status of physical activity, smoking, alcohol consumption, and detailed medical history. Consequently, blood pressure was measured manually with a sphygmomanometer. Body mass index was calculated as weight in kilograms divided by height in square meters. Hypertension was defi ned as systolic blood pressure of at least 140 mm Hg, diastolic blood pressure of at least 90 mm Hg, otherwise physician diagnosed hypertension.
Those with a known past history of any major diseases like cardiac disease, renal, hepatic or endocrine disease were excluded. None of the participants in the present study were using drug medications including anti-hypertensive reagents, diuretics, lipid lowering agents, vitamins or mineral drugs. Subjects with hypertension or osteoporosis, smokers and alcohol users were also excluded.
The subjects were locals with average family income, strongly favoring a common dietary habits, and routine daily life.
Final diagnosis of each patient was confi rmed by histopathologic evaluation of prostate needle biopsies. After the pathology reports were inspected, only the patients with a Gleason scores of 5,6 and 7 were included into the study. Any patients with a clinical or radiologic suspicion of metastatic prostate cancer were excluded.
This study was performed in accordance with the ethical standards set by the Declaration of Helsinki and was approved by the local ethics committee.
Analytical methods
Blood Sample Collection: Blood samples were obtained after an overnight fasting state. Serum samples were then separated from the cells by centrifugation at 3000 rpm for 10 minutes. Serum total PSA (PSA), intact PTH, calcium and cholesterol (TC), triglycerid (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL) levels were measured freshly. Remaining serum portions were stored at -80°C and used to analyze 25(OH) vitamin D and aldosterone.
PTH and PSA levels were measured using the Access Hybridtech two-site immunoenzymatic "sandwich" assay (Beckman Coulter, Fullerton, CA). Serum calcium levels and lipid panel were determined by using commercially available assay kits(Abbott) with an autoanalyzer (Architect ®c16000, Abbott Diagnostics).
The LIAISON® 25 OH Vitamin D assay (DiaSorin) was performed on the LIAISON® analyzer according to the manufacturer's instructions. The LIAISON 25 OH Vitamin D assay is a direct competitive chemiluminescence immunoassay.
Aldosterone was measured through the principle of competitive enzyme immunoassay test(DRG® Aldosterone (EIA-4600) performed on Etimax microelisa analyser.
Statistical analysis
Statistical analyses were carried out using the statistical software version 11.5.1.0 (MedCalc®, Mariakerke, Belgium). In normally distributed groups the results were presented with mean and SD, otherwise with medians. The signifi cance of the differences between groups was determined by Student's unpaired t-test for normal distributions, and by the Mann-Whitney U-test in abnormal distributions. Pearson correlation coeffi cient and Spearman correlation coeffi cient were used to test the strength of any associations between different variables. p values less than 0.05 were accepted as the signifi cance level.
Results
Demographic and clinical data of prostate cancer patients and controls are summarized in Table 1 . The patients and controls were similar in age, BMI and lipid parameters.
We evaluated associations between PSA, total serum calcium, serum intact PTH, serum 25(OH) D, and serum aldosterone levels in patients with PCa, compared to the control group (Tab. 2). Serum PSA levels were signifi cantly higher in PCa patients as 
Fig. 1. 25-(OH)D levels were signifi cantly lower in PCa group compared to the controls (p=0.03). 25-(OH)D levels in both groups
were lower than the threshold reference limit (20 ng/ml).
expected. 25(OH)D levels were signifi cantly lower compared to the controls (p=0.03). Interestingly, 25(OH)D levels in controls were lower than the threshold reference limit (20 ng/ml) (Fig. 1) . Serum PTH, calcium and aldosterone values were indifferent between groups, and were in normal limits. Aldosterone mean difference was very close to the signifi cance value (p=0.06).
Pearson test showed positive correlations between PTH and PSA levels both in PCa and control groups(r=0.54 p=0.005; r=0.48 p=0.006, respectively) (Fig. 2) .
Discussion
Our results were in line with some of the previous ones, supporting the role of vitamin D in PCa (9, 10) . Of concern is that we observed signifi cant positive correlations between serum PTH and serum PSA in both PCa and control groups with very close statistical coeffi cients and p values. The correlation may be explained by PTHs role in regulating serum levels of 1,25(OH)2D and thus its potential effect on prostate cells indirectly. But also it should be kept in mind that normal and cancerous prostate cells possess specifi c receptors for PTH, clearly making a direct and independent effect quite possible. Actually, PTH is a well studied mitogen in the prostate. Administration of PTH increases the proliferation of human prostate cancer cells in tissue culture (11) . Previous studies have already shown that even physiologic levels of PTH promote the growth of prostate cancer cells in tissue culture and in vivo (12) . PTH injection to rats with prostate cancer xenografts has promoted tumor growth and was accompanied by an increase in serum PSA (13) . Epidemiologic studies on serum PTH and prostate disease are very rare. In 2009, an association between serum PTH and serum calcium and serum PSA in men without clinical prostate cancer was presented (14) . In contrast to this study, serum calcium levels in our study did not show a correlation with PSA levels. The close statistical numerical values obtained in both controls and PCa patients were of great interest. The fi nding favors a direct interrelation between PTH and PSA. We believe the relationship is independent of calcium homeostasis mechanism. The lack of correlation between 25(OH) D and PTH was also a hold for our suggestion. In a very recent study, PSA levels were not correlated with PTH or vitamin D or serum calcium levels in patients with benign prostate hyper (BPH) (15) . One of our studies also confi rmed this fi nding (unpublished data). We fi nd the discrepancy valuable, to be an evidence for BPH to own a different pathogenesis from PCa, thus BPH do not progress to a carcinoma.
It seems quite reasonable that the blood levels of 25(OH)D infl uence vitamin D functions in tissues. Yet, it is still unclear to what extent these effects are mediated through direct actions of 25(OH)D or through indirect effects of the hormone on plasma calcium concentration, PTH levels, or other confounding factors. In human body, vitamin D is tightly regulated by PTH and calcium levels through the actions of renal 1α-OHlase. This close relationship is the reason to believe that PTH and calcium can function both directly and indirectly as a cancer promoter. PTH can increase insulin-like growth factor 1 (IGF-I) synthesis in liver and bone, thereby increasing the pool of circulating IGF-I. PTH may act as a direct cancer promoter as a co-mitogen and anti-apoptotic factor in preneoplastic lesions expressing the PTH receptor (16) . Increased intakes of calcium or dairy products have already been associated with decreased risk for colon or breast cancer in several prospective studies (6) .
The independent action, namely the autocrine effect of vitamin D means the conversion of vitamin D prohormone 25(OH)D, into the 1, 25(OH)2D in the target tissue. Identifi cation of extra-renal 1aOHlase has changed our understanding of the precise role of 25(OH)D in tissues including the prostate. Experimentally, it was shown that in peripheral macrophages cultured in serum-free media, synthesis of 1,25(OH)2D was not infl uenced by PTH even at supraphysiological concentrations , but was inhibited by its own reaction product, 1,25(OH)2D at physiological concentrations (17) .
Several 1,25(OH)2D target tissues, including intestinal epithelial cells and the cardiovascular system, also have been identifi ed as sites of nongenomic aldosterone regulation (18) . Our results were short in suggesting a possible role of aldosterone in PCa pathogenesis, but encourage a future study with a larger number of patients.
The apparent limitation of the study was the small number of patients. However, these patients were enrolled in a long period of time, as we excluded any patients with a disease that required medical interventions, in order to separate the measured parameters to be independent.
Our fi ndings indicate that, like age, race, PSA is associated with PTH as presented by very rare previous studies. Prostate cells express calcium-dependent channels that regulate cell proliferation via the control of calcium entry into the cells (19) . The mechanism is not unique to prostate but common all through the body making PTH a general mitogen. Although a major culprit, PTH seems to be neglected in studies of cancer. Our study demonstrated the close relation of PTH with one of the most famous cancer markers, namely PSA. Our results do not include an explanation of the fi nding, but hopefully will inspire future studies on PTH and cancer in general.
